News
Recap: Atea Pharmaceuticals Q4 Earnings
28 Feb 24
Earnings
Atea Pharmaceuticals Q4 2023 GAAP EPS $(0.47) Beats $(0.51) Estimate
28 Feb 24
Earnings, Earnings Beats, News
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Atea Pharmaceuticals Earnings Preview
27 Feb 24
Earnings
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
9 Jan 24
Analyst Color, Biotech, News, Penny Stocks, Health Care, Analyst Ratings, Movers, Trading Ideas, General
Atea Pharmaceuticals Announces Initial Data from Phase 2 Study for Hepatitis C Virus And Significant Enrollment Milestone For Phase 3 SUNRISE-3 Trial For COVID-19
8 Jan 24
Biotech, News, General
Press releases
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
27 Mar 24
Health Care, Press Releases, General
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
8 Jan 24
Health Care, Press Releases, General
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
3 Jan 24
News, Press Releases